Skip to main navigation
Aimmune
  • Contact
Menu CLOSE X
CLOSE X
  • About Us
    • Company Overview
    • History
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
    • Contact
  • Therapeutic Focus
    • Food Allergies
    • CODIT™ & Oral Immunotherapy
    • Helpful Resources
  • Pipeline
    • Development Pipeline
    • AR101 for Peanut Allergy
    • Discovery Program
    • Expanded Access Policy
  • News & Events
    • Press Releases
    • Medical Congresses
    • Media Resources
  • Investor Relations
    • Investor Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Financials & Filings
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor FAQs
  • Contact

Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017

  • Read more about Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017

Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

  • Read more about Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March

  • Read more about Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March

Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

  • Read more about Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback

  • Read more about Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback

Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

  • Read more about Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts

  • Read more about Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts

Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy

  • Read more about Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy

Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science

  • Read more about Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science

Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy

  • Read more about Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Shareholder Tools

  • Print Page
  • Email Alerts
  • IR Contact
  • RSS Feeds
About Us
  • Company Overview
  • History
  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Partners
  • Careers
  • Contact
Therapeutic Focus
  • Food Allergies
  • CODIT™ & Oral Immunotherapy
  • Helpful Resources
Pipeline
  • Development Pipeline
  • AR101 for Peanut Allergy
  • Discovery Program
  • Expanded Access Policy
News & Events
  • Press Releases
  • Medical Congresses
  • Media Resources
Investor Relations
  • Investor Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Financials & Filings
  • Corporate Governance
  • Stock Information
  • Investor FAQs
© 2018 Aimmune Therapeutics.
  • All rights reserved.
  • Terms of Use
  • Twitter Guidelines

Aimmune’s food allergy treatments are investigational and are not FDA-approved.

ShareThis Copy and Paste
Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...